3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Astrocytoma
1
Interventions
Temozolomide
14
Bevacizumab
11
Erlotinib Hydrochloride
5
Radiotherapy
4
Carboplatin
4
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Immunoglobulin G
3
Disulfides
3
temsirolimus
2
poly ICLC
2
palbociclib
2
etoposide phosphate
2
antineoplaston AS 2-1
2
antineoplaston A10
2
Vincristine
2
Sunitinib
2
Sirolimus
2
Everolimus
2
Dasatinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
veliparib
1
varlilumab
1
vandetanib
1
trebananib
1
trametinib
1
terameprocol
1
tandutinib
1
selinexor
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Oligodendroglioma
×
picropodophyllin
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts